LENZ Therapeutics, Inc. (LENZ) EBT (2022 - 2023)
LENZ Therapeutics (LENZ) has disclosed EBT for 2 consecutive years, with -$24.1 million as the latest value for Q4 2023.
- On a quarterly basis, EBT rose 9.77% to -$24.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$75.4 million, a 28.62% increase, with the full-year FY2024 number at -$49.8 million, up 29.05% from a year prior.
- EBT was -$24.1 million for Q4 2023 at LENZ Therapeutics, down from -$23.9 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$12.6 million in Q1 2023 to a low of -$26.8 million in Q2 2022.